Oral immunotherapy for children with a high-threshold peanut allergy.

Ann Allergy Asthma Immunol

Clinical Immunology, Angioedema and Allergy Unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Safra Children's Hospital, Sheba Medical Centre, Tel Hashomer, Israel.

Published: September 2022

AI Article Synopsis

  • Between 25% and 30% of children with peanut allergies have a high-threshold peanut allergy (HTPA), meaning they can tolerate over 100 mg of peanut protein, but this threshold can change due to various factors.
  • The study aimed to assess the feasibility of a 40-week oral immunotherapy (OIT) for children with HTPA, using two dosage strategies.
  • Out of 28 enrolled children, most successfully completed the OIT protocol, and after 6 months, the average tolerated dosage increased to 8 g, allowing for the safe inclusion of peanuts in their diets.

Article Abstract

Background: Between 25% and 30% of children with peanut allergy (PA) have a relatively high-threshold peanut allergy (HTPA), with a single maximal tolerated dose (SMTD) higher than 100 mg of peanut protein (PP). However, this threshold may decrease with time, age, exercise, illness, sleep deprivation, and other covariates.

Objective: To explore the feasibility of a simplified oral immunotherapy (OIT) protocol in a group of children with HTPA.

Methods: Children with PA with an SMTD higher than 100 mg were placed on a 40-week OIT protocol of either 300 mg/d of PP or 100 mg/d for 20 weeks followed by 300 mg/d for 20 weeks. A repeat open peanut food challenge was performed after 40 weeks of treatment and at a 6-month follow-up visit. After the 40-week challenge, all children received a maintenance dosage of 2 gPP 3 times a week.

Results: A total of 28 children with HTPA were enrolled, with 56% boys, 89% younger than 6 years old, and a mean SMTD of 304 mg (95% confidence interval 229-378). All were placed on the described OIT protocol. Overall, 2 children were not compliant and 3 had allergic reactions at home on the dose previously tolerated in clinic, 23 completed the 40-week protocol, and all were able to consume 2 g of PP. The mean tolerated dosage at the 6-month follow-up was 8 g. This enabled most children age-appropriate dietary inclusion of peanut-containing products.

Conclusion: In children with HTPA, a simple, fixed-dose OIT can be both safe and efficacious.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anai.2022.05.001DOI Listing

Publication Analysis

Top Keywords

peanut allergy
12
oit protocol
12
children
9
oral immunotherapy
8
high-threshold peanut
8
smtd higher
8
higher 100
8
300 mg/d
8
mg/d weeks
8
6-month follow-up
8

Similar Publications

M13 bacteriophage based fluorescence immunoassay against food allergens of Ara h 3 and Mac i 1.

Food Chem

December 2024

Tianjin Key Laboratory of Food Science and Health, School of Medicine, Nankai University, Tianjin 300071, China. Electronic address:

Food allergy is increasingly prevalent and poses notable health risks, which underscores the urgent need to develop reliable and sensitive detection methods for effective identification of food allergens. This study aims to address the limitations of existing methods by developing an immunoassay utilizing bacteriophage/carbon dots (CDs)@silica core-shell nanospheres. Two CDs with different emission wavelengths (513 nm for Green CDs, 645 nm for Red CDs) were synthesized for signal development and amplification.

View Article and Find Full Text PDF

Massive Screening of Food Extracts for Quality Assessment and Standardization of Allergenic Activity.

Biosensors (Basel)

December 2024

Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, Camino de Vera s/n, E46022 Valencia, Spain.

(1) Background: In drug discovery and pharmaceutical quality control, a challenge is to assess protein extracts used for allergy therapy and in vivo diagnosis, such as prick tests. Indeed, there are significant differences between the features of marketed products due to variations in raw materials, purification processes, and formulation techniques. (2) Methods: A protein array technology has been developed to provide comprehensive information on protein-biomarker interactions on a large scale to support the pharmaceutical industry and clinical research.

View Article and Find Full Text PDF

Background: Remission is the desired outcome following OIT as it allows individuals to discontinue treatment and eat the allergen freely. Early initiation of OIT in infants and toddlers has been embraced as an approach to increase the likelihood of remission. However, there is no high-quality evidence supporting younger age as an independent factor driving remission; available studies are limited by small samples of younger subjects and lack of adjustment for confounding covariates, particularly peanut-specific IgE (sIgE) levels which is closely correlated with age.

View Article and Find Full Text PDF

[Diagnosis of soybean and peanut allergen components: identification of major components and clinical management strategies].

Zhonghua Yu Fang Yi Xue Za Zhi

December 2024

Department of Clinical Laboratory of the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou510120, China.

Soybeans and peanuts belong to the leguminous family and are common causes of food anaphylaxis. Symptoms range from oral allergy syndrome to severe breathing difficulties, anaphylactic shock, and even death. But the allergens causing allergies are different, and the severity of symptoms are different.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!